Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.
Esther CR Jr, Muhlebach MS, Ehre C, Hill DB, Wolfgang MC, Kesimer M, Ramsey KA, Markovetz MR, Garbarine IC, Forest MG, Seim I, Zorn B, Morrison CB, Delion MF, Thelin WR, Villalon D, Sabater JR, Turkovic L, Ranganathan S, Stick SM, Boucher RC. Esther CR Jr, et al. Among authors: sabater jr. Sci Transl Med. 2019 Apr 3;11(486):eaav3488. doi: 10.1126/scitranslmed.aav3488. Sci Transl Med. 2019. PMID: 30944166 Free PMC article.
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.
Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R, Boyer J, Abraham WM, Boucher RC. Yerxa BR, et al. Among authors: sabater jr. J Pharmacol Exp Ther. 2002 Sep;302(3):871-80. doi: 10.1124/jpet.102.035485. J Pharmacol Exp Ther. 2002. PMID: 12183642
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.
Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, Johnson KB, St George JA, Johnson MR, Boucher RC. Hirsh AJ, et al. Among authors: sabater jr. J Pharmacol Exp Ther. 2008 Apr;325(1):77-88. doi: 10.1124/jpet.107.130443. Epub 2008 Jan 24. J Pharmacol Exp Ther. 2008. PMID: 18218832
Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.
Terryah ST, Fellner RC, Ahmad S, Moore PJ, Reidel B, Sesma JI, Kim CS, Garland AL, Scott DW, Sabater JR, Carpenter J, Randell SH, Kesimer M, Abraham WM, Arendshorst WJ, Tarran R. Terryah ST, et al. Among authors: sabater jr. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L192-L205. doi: 10.1152/ajplung.00546.2016. Epub 2017 Oct 5. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 28982737 Free PMC article.
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Kim MD, Baumlin N, Yoshida M, Polineni D, Salathe SF, David JK, Peloquin CA, Wanner A, Dennis JS, Sailland J, Whitney P, Horrigan FT, Sabater JR, Abraham WM, Salathe M. Kim MD, et al. Among authors: sabater jr. Am J Respir Crit Care Med. 2020 Feb 1;201(3):313-324. doi: 10.1164/rccm.201905-0990OC. Am J Respir Crit Care Med. 2020. PMID: 31613648 Free PMC article.
Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion.
Tarran R, Sabater JR, Clarke TC, Tan CD, Davies CM, Liu J, Yeung A, Garland AL, Stutts MJ, Abraham WM, Phillips G, Baker WR, Wright CD, Wilbert S. Tarran R, et al. Among authors: sabater jr. Am J Physiol Lung Cell Mol Physiol. 2013 Jun 1;304(11):L746-56. doi: 10.1152/ajplung.00292.2012. Epub 2013 Mar 29. Am J Physiol Lung Cell Mol Physiol. 2013. PMID: 23542952 Free PMC article.
32 results